Cancer Biomarker Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Cancer Biomarker Market: By Biomarker Type (Protein Biomarker, Genetic Biomarker, Others), By Cancer Type (Breast Cancer , Lung Cancer, Prostate Cancer, Non-Hodgkin’s Lymphoma, Bladder Cancer, Kidney Cancer, Liver Cancer, Others), By Profiling Technology (OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, Bioinformatics, Others), By Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

The global cancer biomarkers market size valued at USD 15.06 billion in 2021 and expected to reach USD 31.53 billion by 2028 witnessing a CAGR rate of 11.5% during the forecast period 2022-2028. For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, rise in R&D for the development of newer biomarkers, raise in funding from public and private sectors, increase in adoption of cancer biomarkers for drug discovery and development, and surge in demand for early stage disease diagnosis are expected to propel the market over the forecast years. However, stringent regulations for the product approval, high cost for the R&D, and lack of favorable reimbursement guidelines are hamper the growth of market over the forecast years. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global cancer biomarker market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global cancer biomarker market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).

Cancer Biomarker Market

MARKET SUMMARY
-
11.5% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 11.5%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Cancer Biomarker Market

  • The report on global cancer biomarker market gives historical, current and future market sizes (US$ Bn) on the basis of biomarker type, cancer type, profiling technology, application and region.
  • cancer biomarker market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • Key stakeholders of the market include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global cancer biomarker products.
Key Players
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Hoffmann La Roche Ltd.
  • Hologic, Inc.
Cancer Biomarker Market

Drivers And Restraints

Increase in the R&D for the development of newer products is a major factor drive the global cancer biomarker market over the forecast years. For instance, in May 2019, Roche Diagnostics launched HER2 biomarker that can detect the breast and gastric cancer. Moreover, raise in funding for R&D also boost the market over the forecast timeframe. For instance, in March 2016, The National Cancer Institute has reserved $5.5 million in 2016 to fund the establishment of laboratories to advance research on biomarkers and biomarker assays for cancers of the breast, prostate, lung, and genitourinary organs.


North-America got significant share

Cancer Biomarker Market

North America accounted for major revenue share due to increased rates of certain types of cancers in U.S. and Canada. For instance, according to National Cancer Institute 208, approximately 1,735,350 cases diagnosed with cancer in United States. Moreover, Europe cancer biomarker market contributed highest growth rate in 2018 and expected to grow at 5.6% CAGR over the forecast years owing to increase in research and development on newer technologies, and favorable reimbursement policies in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Findings of the Report

  • Global cancer biomarker market expanding at significant CAGR over 2022 to 2028 owing to increase in the prevalence of cancer disease.
  • Based on biomarker type, protein biomarker accounted for larger market revenue share in 2021 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global cancer biomarker market

Key

Key Features of the Report

Cancer Biomarker Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Hoffmann La Roche Ltd.
  • Hologic, Inc.
  • Creative Diagnostics
  • Quest Diagnostics
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Exact Sciences
  • Meso Scale Diagnostics LLC
  • Seegene Technologies Inc.
  • Siemens Healthineers

Description

The global cancer biomarkers market size valued at USD 15.06 billion in 2021 and expected to reach USD 31.53 billion by 2028 witnessing a CAGR rate of 11.5% during the forecast period 2022-2028. For instance, according to WHO 2018 data, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, rise in R&D for the development of newer biomarkers, raise in funding from public and private sectors, increase in adoption of cancer biomarkers for drug discovery and development, and surge in demand for early stage disease diagnosis are expected to propel the market over the forecast years. However, stringent regulations for the product approval, high cost for the R&D, and lack of favorable reimbursement guidelines are hamper the growth of market over the forecast years. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global cancer biomarker market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global cancer biomarker market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX